<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEFTIBUTEN</span><br/>(sef-ti-bu'ten)<br/><span class="topboxtradename">Cedax<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">beta-lactam antibiotic</span>; <span class="classification">third-generation cephalosporin</span><br/><b>Prototype: </b>Cefotaxime sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>400 mg capsules; 90 mg/5 mL, 180 mg/5 mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Ceftibuten is a broad-spectrum, third-generation beta-lactam antibiotic. Preferentially binds to one or more of the penicillin-binding
         proteins located in the cell wall of susceptible organisms. This inhibits third and final stage of bacterial cell wall synthesis,
         thus killing the bacterium. It is highly resistant to hydrolysis by most beta-lactamase bacteria.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It has antibacterial activity against both gram-negative and gram-positive bacteria, including <i>Haemophilus influenzae</i> (beta-lactamaseproducing strains also), <i>Streptococcus pneumoniae,</i> and <i>Streptococcus pyogenes</i>. Effectively treats bronchitis, otitis media, pharyngitis, and urinary tract infections, reducing or eliminating infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Acute bacterial exacerbations of chronic bronchitis caused by <i>H. influenzae, Moraxella catarrhalis,</i> or <i>S. pneumoniae;</i> acute bacterial otitis media caused by <i>H. influenzae, M. catarrhalis,</i> or <i>S. pyogenes;</i> pharyngitis or tonsillitis caused by <i>S. pyogenes.</i>
</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ceftibuten or cephalosporins.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal dysfunction, penicillin hypersensitivity, history of colitis or diabetes, pregnancy (category B), lactation. Safety
         and efficacy in infants 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Mild to Moderate Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg once daily for 10 d<br/><br/><span class="impairmenttitle">Renal Insufficiency</span><br/>Cl<sub>cr</sub> 3049: 200 mg q24h; Cl<sub>cr</sub> <span class="rdage">Child <i>(6 mo12 y)</i>
                  				:</span> <span class="rdroute">PO</span> 9 mg/kg once daily (max: 400 mg) for 10 d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 3049 mL/min: 4.5 mg/kg q24h; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give oral suspension 1 h before or 2 h after a meal.</li>
<li>Children weighing more than 45 kg may receive maximum daily dose.</li>
<li>Hemodialysis patients should receive drug at the end of dialysis.</li>
<li>Store capsules at 2°25° C (36°77° F); keep container tightly closed. Reconstituted oral suspension
            is stable for 14 d under refrigeration at 2°8° C (36°46° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Dyspnea, dysuria, fatigue, vaginitis, moniliasis, urticaria, pruritus, rash, paresthesia, taste perversion. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, dyspepsia, abdominal pain, anorexia, constipation, dry mouth, eructation, flatulence. <span class="typehead">CNS:</span> Headache, dizziness, nasal congestion, somnolence. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">aminoglycosides</span> may increase risk of nephrotoxicity and have additive/synergistic effects. May decrease efficacy of <span class="classification">oral contraceptives</span>. <b>Probenecid</b> may increase levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Peak:</span> Approx. 23 h. <span class="typehead">Distribution:</span> Bronchial mucosa levels are approx 37% of plasma levels, middle ear levels approx 50% of plasma levels. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 1.52.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine history of hypersensitivity reactions to cephalosporins, penicillins, or other drugs, before therapy is initiated.
            Monitor for S&amp;S of hypersensitivity (see Appendix F); report their appearance promptly and discontinue drug.
         </li>
<li>Lab tests: Perform culture and sensitivity tests before initiation of therapy. Dosage may be started pending test results.</li>
<li>Monitor for S&amp;S of superinfection or pseudomembranous colitis (see Appendix F); immediately report either to physician.</li>
<li>Closely monitor patients with renal impairment; if seizures develop, discontinue drug and notify physician.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>If on dialysis treatment, take this drug after dialysis.</li>
<li>Report any S&amp;S of hypersensitivity, superinfection, and pseudomembranous colitis promptly.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>